Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.

  title={Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.},
  author={J. Rouffy and B. Chanu and R. Bakir and F. Djian and J. Goy-Loeper},
  volume={54 3},
In a double-blind study over a 3-month period, a daily dose of 100 mg ciprofibrate, prescribed in a single administration and a daily dose of 300 mg fenofibrate, prescribed in 3 administrations, significantly reduced the mean values of total cholesterol, LDL cholesterol and VLDL cholesterol, apoprotein B (P less than 0.001) and increased the mean values of HDL cholesterol (P less than 0.01) and total apoprotein A (P less than 0.05). The study, followed-up as an open trial using higher doses… Expand
27 Citations
Effect of ciprofibrate in patients with primary hypercholesterolemia: a 6-year pilot study
100 mg/d of ciprofibrate, administered for 6 years to patients with primary isolated or mixed hypercholesterolemia, was effective and well tolerated and further controlled studies in larger groups of patients are needed to fully confirm these promising results. Expand
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
Ciprofibrate and gemfibrozil have comparable short-term efficacy and safety profiles, and ciproFibrate reduces fibrinogen levels and benefits from a once daily regimen. Expand
Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Fenofibrates offers an effective and well tolerated alternative to clofibrate or other fibric acid derivatives, but its relative efficacy and tolerability compared with other types of lipid-lowering drugs, and its effect on cardiovascular morbidity and mortality, remain to be clarified. Expand
Comparison of simvastatin and ciprofibrate in the treatment of primary hypercholesterolaemia — a French multicentre study
The effects of simvastatin on total and LDL-cholesterol are greater than those of ciprofibrate, regardless of the levels of total cholesterol and triglycerides prior to treatment, in patients with primary hypercholesterolaemia. Expand
Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent
  • D. Guay
  • Medicine
  • The Annals of pharmacotherapy
  • 1999
Fenofibrate reduces serum TG, total cholesterol, and LDL-C, and raises HDL-C to clinically relevant degrees, and may be considered a broader-spectrum fibrate than is indicated by its FDA approval. Expand
An Overview of Lipid-Lowering Drugs
Combined therapy with drugs which have different mechanisms of action can be effectively used in the treatment of patients with severe hypercholesterolaemia or combined hyperlipidaemia; for the former group, combinations which use bile acid sequestrants, HMG CoA reductase inhibitors and nicotinic acid are the most effective. Expand
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Therapy with fenofibrate, bezafibrates, and ciprofibrate may induce renal dysfunction, and gemfibrozil appears to be devoid of this side-effect. Expand
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
The evidence suggests that bezafibrate, ciprofibrates, and fenofibrates may produce greater reductions in low-density lipoprotein cholesterol than those usually observed with clofibrate and gemfibrozil. Expand
10 Mode of action of lipid-lowering drugs
It is not yet certain whether all the approaches to cholesterol lowering have equal validity, although an effect on biological endpoints is obtained for a variety of agents. Expand
Treatment of hypercholesterolaemia with fenofibrate: a review.
  • W. Brown
  • Medicine
  • Current medical research and opinion
  • 1989
Based on its efficacy and tolerability profile, fenofibrate would appear to be an appropriate choice for treatment of hypercholesterolaemia in selected patients. Expand


Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
It is concluded from this study that it would be appropriate to start patients with hyperlipoproteinaemia on 100 mg daily and then titrate their dose according to response, and the optimal dosage for ciprofibrate seems to be 200 mg daily. Expand
Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
Once daily therapy with 100 mg ciprofibrate, is effective in reducing LDL levels in patients with type II hypercholesterolemia (mainly heterozygous FH) and that this decrease is paralleled by small rises in HDL. Expand
Classification of hyperlipidaemias and hyperlipoproteinaemias.
The present memorandum presents a classification of the main types of hyperlipidaemia, based on lipoprotein analyses by electrophoresis and ultracentrifugation, and briefly describes the criteria for diagnosis as well as the methods of their determination. Expand
The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
The relatively low density of the lipoproteins was utilized by Lindgren, Elliott, and Gofman to separate them from the other serum proteins by ultracentrifugal flotation, and quantitation was subsequently performed by refractometric methods in the analytical ultracentRifuge. Expand
Immunochemical determination of human apolipoprotein A-I by laser nephelometry.
The Hyland laser nephelometer PDQ system for the assay of apolipoprotein B (apo-B) in human serum is described, and the speed, precision, and convenience of the methodology make such a system attractive. Expand